ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 59 citations in OpenAlex.
- Freezing nitrogen ethanol composite as an alternative to liquid nitrogen in giant cell tumor cryotherapy: a case report and literature review.International journal of surgery case reports · 2026Article
- Giant Cell Tumor of Bone: Biology, Pathophysiology, and Histopathology in the Era of H3F3A.Biomedicines · 2026Review
- Evaluation of Morphological and Immunohistochemical Prognostic Parameters in Giant Cell Tumor of Bone.Turk patoloji dergisi · 2026Article
- Clinical Audit of Denosumab Biosimilar for Aggressive GCT of Bone: A Tertiary Care Center Retrospective Analysis.South Asian journal of cancer · 2025Article
- Clinical pathological characteristics correlation ofTranslational cancer research · 2025Article
- A comprehensive review and advanced biomolecule-based therapies for osteoporosis.Journal of advanced research · 2025Review
- Immunohistochemical Characterization of Feline Giant Cell Tumor of Bone (GCTb): What We Know and What We Can Learn from the Human Counterpart.Animals : an open access journal from MDPI · 2025Article
- (B)On(e)-cohistones and the epigenetic alterations at the root of bone cancer.Cell death and differentiation · 2025Review
- Benign bone and soft tissue tumors of the foot.EFORT open reviews · 2024Review
- Giant-cell-poor giant cell tumor of bone: report of two cases and literature review.Skeletal radiology · 2023Review
- Anticancer Potential of the Cyclolinopeptides.Cancers · 2023Review
- Plexiform fibrohistiocytic tumor: a clinicopathological and immunohistochemical study of 39 tumors, with evidence for a CSF1-producing "null cell" population.Virchows Archiv : an international journal of pathology · 2022Article
- Siglec-15 as a New Perspective Therapy Target in Human Giant Cell Tumor of Bone.Current oncology (Toronto, Ont.) · 2022Article
- Premalignant Conditions of Bone.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2022Article
- Single-cell RNA sequencing reveals differential expression of EGFL7 and VEGF in giant-cell tumor of bone and osteosarcoma.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- State of the Art and New Concepts in Giant Cell Tumor of Bone: Imaging Features and Tumor Characteristics.Cancers · 2021Review
- LIM Kinases in Osteosarcoma Development.Cells · 2021Review
- Serglycin induces osteoclastogenesis and promotes tumor growth in giant cell tumor of bone.Cell death & disease · 2021Article
- Article
- Establishment and characterization of NCC-GCTB1-C1: a novel patient-derived cancer cell line of giant cell tumor of bone.Human cell · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell tumor is a relatively uncommon but painful tumor of bone, which can metastasize to the lungs. The RANK pathway is often reported to be involved in the pathogenesis of giant cell tumor of bone (GCTB). This pathway is a key signaling pathway of bone remodeling that plays a critical role in differentiation of precursors into multinucleated osteoclasts, and activation of osteoclasts leading to bone resorption. Dysregulation of RANK ligand (RANKL)-RANK-osteoprotegerin (OPG) signaling cascade induces the imbalance between bone formation and bone resorption, which leads to the changes in bone mass, increases osteoclast-mediated bone destruction, bone metastasis, and the progression of existing skeletal tumors. Recent evidences have shown that targeting the components of RANKL-RANK-OPG signaling pathway is a promising approach in the treatment of GCTB. This review study has focused on the association of RANKL-RANK-OPG pathway in the pathogenesis and progression of GCTB as well as discussed the possible therapeutic strategies by targeting this pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.